Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D.

Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial standing was strengthened by a $125 million share offering, which is expected to support its operations and capital expenditures beyond 2025. Despite promising initial results, the company faces competition in the gene therapy landscape for sickle cell disease and must continue to provide robust data as trials progress.

Editas Medicine Bolsters Cash Position Amidst Slow And Steady Progress

bluebird bio

CRISPR Therapeutics

Intellia Therapeutics

Some gene therapies are very expensive to manufacture. Those difficulties caused one developer to exit the E.U.

This 1 Problem Could Sink at Least 4 Gene-Editing Stocks

Its most advanced drug candidate is still far from regulatory approval. The small-cap biotech could run into funding problems ahead.

Is Editas Medicine Stock a Buy Now?

Editas Medicine is issuing new stock, and that made its share price fall. The new funds will pay for less than one full year of operating expenses.

After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?

Short-sellers have been ramping up their positions in both Editas Medicine and Bluebird Bio lately. With multiple options on the table, Editas and Bluebird could both blaze the comeback trail.

2 Short-Squeeze Candidates That Could Go Parabolic

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds from the offering are expected to be approximately $125 million. Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on or about June 20, 2023, subject to customary closing conditions.

Editas Medicine Announces Pricing of Offering of Common Stock

CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional $18.8 million of shares of its common stock. All of the shares in the offering are to be sold by Editas Medicine.

Editas Medicine Announces Offering of Common Stock

Editas (EDIT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains?

Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Clinical Update Conference Call June 12, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications & Investor Relations Gilmore O'Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Erick Lucera - Chief Financial Officer Conference Call Participants Joon Lee - Truist Securities Phil Nadeau - Cowen & Company Jacques Villefranc - Stifel Lisa Walter - RBC Capital Markets Jay Olson - Oppenheimer Yanan Zhu - Wells Fargo Madhu Kumar - Goldman Sachs Steven Seedhouse - Raymond James Samantha Semenkow - Citi Cristi Barnett Good morning, everyone and thank you for joining the EDIT-301 Clinical Update Webinar. This webinar is being recorded and can be accessed in the future through this same link or through the Investors section of the company's website.

Editas Medicine, Inc. (EDIT) EDIT-301 Clinical Update Call Transcript

Editas (EDIT) announces positive preliminary safety and efficacy data from patients treated with its lead drug, EDIT-301, in the RUBY and EdiTHAL studies to treat SCD and TDT, respectively.

Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

Invitae

An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m.

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?

CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, at 8:00 a.m. ET to present clinical data from the RUBY trial of EDIT-301 for the treatment of severe sickle cell disease. The Company will also present initial clinical data from the EDITHAL trial of EDIT-301 for the treatment of transfusion-dependent beta thalassemia.

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

Cinemark Holdings

World Acceptance

Beyond Meat

Chewy

The Beauty Health Company

Trupanion

A practice designed for only the most daring traders, the best short-squeeze stocks to buy now could yield tremendous gains. To be sure, approaching this sector means staring at the possibility of severe losses in the face.

7 Short-Squeeze Stocks Set for a May Rally

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company's newly appointed Chief Financial Officer, Erick Lucera. In connection with Mr. Lucera's appointment, the Editas Medicine Board of Directors approved a stock option grant to Mr. Lucera as an inducement material to Mr. Lucera entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 155,800 shares of Editas Medicine common stock at a price of $9.61 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Mr. Lucera's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Mr. Lucera's continued service relationship with Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grant to New Chief Financial Officer

CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J.

Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

Editas Medicine, Inc. (NASDAQ:EDIT ) RBC Capital Markets Global Healthcare Conference 2023 May 16, 2023 10:30 AM ET Company Participants Gilmore O'Neill – Chief Executive Officer Baisong Mei – Senior Vice President and Chief Medical Officer Conference Call Participants Luca Issi – RBC Capital Markets Luca Issi All right, great, thanks. Hello, everybody.

Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference 2023 Transcript

Editas Medicine, Inc. (NASDAQ:EDIT ) Bank of America Global Healthcare Conference Call May 9, 2023 8:00 PM ET Company Participants Gilmore O'Neill - President, CEO & Director Conference Call Participants Gregory Harrison - Bank of America Merrill Lynch Gregory Harrison Final session of the first day of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA.

Editas Medicine, Inc. (EDIT) Bank of America Global Healthcare Conference Call Transcript

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in patients with severe sickle cell disease has been accepted for an oral presentation at the European Hematology Association (EHA) Hybrid Congress being held June 8-11, 2023, in Frankfurt, Germany, and via live stream.

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

EMERYVILLE, Calif.--(BUSINESS WIRE)--Cynthia Collins joins Nutcracker Therapeutics with more than four decades of experience working in the pharmaceutical and biotech industry.

Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directors

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.

Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2023 Results Conference Call May 5, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - Chief Medical Officer Michelle Robertson - CFO Conference Call Participants Joon Lee - Truist Securities Samantha Semenkow - Citi Dae Gon Ha - Stifel Steve Seedhouse - Raymond James Yanan Zhu - Wells Fargo Ernie Rodriguez - Cowen Rick Bienkowski - Cantor Fitzgerald Rich Law - Credit Suisse Ry Forseth - Guggenheim Luca Issi - RBC Capital Markets Cheng Li - Oppenheimer Operator Good morning, and welcome to Editas Medicine's First Quarter Conference Call. All participants are now in a listen-only mode.

Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call Transcript

Editas Medicine (EDIT) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.74 per share a year ago.

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar

News for Editas Medicine Stock (EDIT)